Patents by Inventor Christopher J. Schmidt
Christopher J. Schmidt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7146837Abstract: A tool for crimping work pieces to one another is disclosed. The tool is mounted on a power actuator having a reciprocating ram for effecting crimping. The tool includes a body engageable with the workpiece. A movable head is mounted on the body and receives the ram. A jaw is pivotably mounted on the body. A link connects the head to the jaw, which pivots in response to the ram engaging and moving the head. The jaw has a tooth that penetrates the work pieces upon pivoting of the jaw. Penetration of the work pieces by the tooth crimps the pieces to one another. A receiver is mounted on the body to permit its engagement with the actuator by means of an attachment device adapted to a particular actuator. The tool may be removably attachable to the actuator or permanently attached thereto.Type: GrantFiled: September 15, 2004Date of Patent: December 12, 2006Inventor: Christopher J. Schmidt
-
Publication number: 20040162294Abstract: The invention provides a method for treating certain neurologic and psychiatric disorders in mammals, including humans, comprising administration of a selective PDE10 inhbitor. In particular, the invention relates to treatment of mood, movement, and anxiety disorders; psychosis; drug, for example alcohol, addiction; disorders having as a symptom deficient cognition; and neurodegenerative disorders and conditions. The invention furthermore provides the use of papaverine as a selective inhibitor of PDE10. The invention also provides assays for identifying chemical compounds that have activity as selective PDE10 inhibitors.Type: ApplicationFiled: February 13, 2004Publication date: August 19, 2004Applicant: Pfizer IncInventors: Lorraine A. Lebel, Frank S. Menniti, Christopher J. Schmidt
-
Publication number: 20040162293Abstract: The invention provides a method for treating certain neurologic and psychiatric disorders in mammals, including humans, comprising administration of a selective PDE10 inhbitor. In particular, the invention relates to treatment of mood, movement, and anxiety disorders; psychosis; drug, for example alcohol, addiction; disorders having as a symptom deficient cognition; and neurodegenerative disorders and conditions. The invention furthermore provides the use of papaverine as a selective inhibitor of PDE10. The invention also provides assays for identifying chemical compounds that have activity as selective PDE10 inhibitors.Type: ApplicationFiled: February 13, 2004Publication date: August 19, 2004Applicant: Pfizer IncInventors: Lorraine A. Lebel, Frank S. Menniti, Christopher J. Schmidt
-
Publication number: 20040048856Abstract: The present invention relates to compounds that are useful exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibitors, and their pharmaceutically acceptable salts, and their use in the treatment of central nervous system and other disorders.Type: ApplicationFiled: September 4, 2003Publication date: March 11, 2004Applicant: Pfizer IncInventors: Harry R. Howard, Christopher J. Schmidt, Thomas F. Seeger, Mark L. Elliott
-
Patent number: 6677378Abstract: The present invention relates to compounds of the formula wherein R1 through R4, X, Y, m and n are defined as in the specification. Such compounds are useful exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibitors, and their pharmaceutically acceptable salts, and their use in the treatment of central nervous system and other disorders.Type: GrantFiled: April 30, 2001Date of Patent: January 13, 2004Assignee: Pfizer Inc.Inventors: Harry R. Howard, Jr., Christopher J. Schmidt, Thomas F. Seeger, Mark L. Elliott
-
Publication number: 20040001895Abstract: The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a CNS-penetrant NK-1 receptor antagonist (e.g., a substance P receptor antagonist) in combination with a PDE IV inhibitor. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a CNS-penetrant NK-1 receptor antagonist and a PDE IV inhibitor.Type: ApplicationFiled: March 13, 2003Publication date: January 1, 2004Applicant: Pfizer Inc.Inventors: Susan B. Sobolov-Jaynes, Christopher J. Schmidt, Lorraine A. Lebel
-
Publication number: 20030235631Abstract: The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a PDE IV inhibitor in combination with an antidepressant or an anxiolytic agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a PDE IV inhibitor and an anxiolytic agent or antidepressant.Type: ApplicationFiled: March 12, 2003Publication date: December 25, 2003Applicant: Pfizer Inc.Inventors: Susan B. Sobolov-Jaynes, Christopher J. Schmidt
-
Publication number: 20030121069Abstract: The invention features non-human mammals and animal cells that contain a targeted disruption of a phosphodiesterase 10A (PDE10A) gene.Type: ApplicationFiled: December 19, 2002Publication date: June 26, 2003Applicant: Pfizer Inc.Inventors: Frank S. Menniti, Christopher J. Schmidt, Jeffrey L. Stock, Christine A. Strick
-
Publication number: 20030032579Abstract: The invention provides a method for treating certain neurologic and psychiatric disorders in mammals, including humans, comprising administration of a selective PDE10 inhbitor. In particular, the invention relates to treatment of mood, movement, and anxiety disorders; psychosis; drug, for example alcohol, addiction; disorders having as a symptom deficient cognition; and neurodegenerative disorders and conditions. The invention furthermore provides the use of papaverine as a selective inhibitor of PDE10. The invention also provides assays for identifying chemical compounds that have activity as selective PDE10 inhibitors.Type: ApplicationFiled: June 20, 2002Publication date: February 13, 2003Applicant: Pfizer Inc.Inventors: Lorraine A. Lebel, Frank S. Menniti, Christopher J. Schmidt
-
Publication number: 20030018047Abstract: The invention provides a method for treating certain neurologic and psychiatric disorders in mammals, including humans, comprising administration of a selective PDE10 inhbitor. In particular, the invention relates to treatment of mood, movement, and anxiety disorders; psychosis; drug, for example alcohol, addiction; disorders having as a symptom deficient cognition; and neurodegenerative disorders and conditions. The invention furthermore provides the use of papaverine as a selective inhibitor of PDE10. The invention also provides assays for identifying chemical compounds that have activity as selective PDE10 inhibitors.Type: ApplicationFiled: May 3, 2002Publication date: January 23, 2003Applicant: Pfizer Inc.Inventors: Lorraine A. Lebel, Frank S. Menniti, Christopher J. Schmidt
-
Publication number: 20030008806Abstract: The invention provides a method for treating certain neurologic and psychiatric disorders in mammals, including humans, comprising administration of a selective PDE10 inhbitor. In particular, the invention relates to treatment of mood, movement, and anxiety disorders; psychosis; drug, for example alcohol, addiction; and disorders having as a symptom deficient cognition. The invention furthermore provides the use of papaverine as a selective inhibitor of PDE10.Type: ApplicationFiled: April 19, 2002Publication date: January 9, 2003Applicant: Pfizer IncInventors: Lorraine A. Lebel, Frank S. Menniti, Christopher J. Schmidt
-
Publication number: 20020143003Abstract: The present invention relates to compounds of the formula 1Type: ApplicationFiled: April 30, 2001Publication date: October 3, 2002Inventors: Harry R. Howard, Christopher J. Schmidt, Thomas F. Seeger, Mark L. Elliott
-
Patent number: 5874445Abstract: The present invention is directed to a new 5HT.sub.2 antagonist, (+)-.alpha.-(2,3-dimethoxyphenyl)-1-?2-(4-fluorophenyl)ethyl!-4-piperidine methanol, and its use in the treatment of a number of disease states.Type: GrantFiled: October 2, 1997Date of Patent: February 23, 1999Assignee: Merrell Pharmaceutical, Inc.Inventors: Albert A. Carr, John M. Kane, David A. Hay, Christopher J. Schmidt
-
Patent number: 5721249Abstract: The present invention is directed to a new 5HT.sub.2 antagonist, (+)-.alpha.-(2,3-dimethoxyphenyl)-1-?2-(4-fluorophenyl)ethyl!-4-piperidine methanol, and its use in the treatment of a number of disease states.Type: GrantFiled: June 7, 1995Date of Patent: February 24, 1998Assignee: Merrell Pharmaceuticals Inc.Inventors: Albert A. Carr, John M. Kane, David A. Hay, Christopher J. Schmidt
-
Patent number: 5618824Abstract: The present invention is directed to 5-HT.sub.2 antagonists and their use as agents in the treatment of obsessive-compulsive disorders (OCD). The invention is particularly directed to the compound (+)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidine methanol which is a member of a class of 5-HT.sub.2 antagonists known as N-aralkyl piperidinemethanol derivatives which are potent and selective inhibitors of the binding of serotonin at the 5-HT.sub.2 receptor site.Type: GrantFiled: March 9, 1994Date of Patent: April 8, 1997Assignee: Merrell Pharmaceuticals Inc.Inventors: Christopher J. Schmidt, John H. Kehne, Robert A. Padich
-
Patent number: 5561144Abstract: The present invention is directed to a new 5HT.sub.2 antagonist, (+)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidine methanol, and its use in the treatment of a number of disease states.Type: GrantFiled: January 13, 1995Date of Patent: October 1, 1996Assignee: Merrell Pharmaceuticals Inc.Inventors: Albert A. Carr, John M. Kane, David A. Hay, Christopher J. Schmidt
-
Patent number: 5500433Abstract: The present invention is directed to a new class of piperidinyl medicinal agents which are useful for treating drug abuse.Type: GrantFiled: January 10, 1995Date of Patent: March 19, 1996Assignee: Merrell Pharmaceuticals Inc.Inventors: Albert A. Carr, Richard C. Dage, John E. Koerner, Tung Li, Francis P. Miller, Thaddeus R. Nieduzak, Mark W. Dudley, . Christopher J. Schmidt, Robert A. Frank
-
Patent number: 5134149Abstract: The present invention is directed to a new 5HT.sub.2 antagonist, (+)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidine methanol, and its use in the treatment of a number of disease states.Type: GrantFiled: July 26, 1991Date of Patent: July 28, 1992Assignee: Merrell Dow Pharmaceuticals Inc.Inventors: Albert A. Carr, John M. Kane, David A. Hay, Christopher J. Schmidt